For the next three years, the protective benefits of the BCG vaccination against Mycobacterium tuberculosis infection will be assessed in both vaccinated and unprotected groups.
As part of a research to ascertain the vaccination’s effectiveness in preventing adult Mycobacterium Tuberculosis infection, the health department has given the Bacillus Calmette-Guerin (BCG) vaccine to over 4,524 adults in the Pune area, according to officials.
As a component of a statewide trial that commenced on September 3, these adults received vaccines. Pune district has been split into two groups for the study: the interventional group (Pimpri-Chinchwad and Pune Rural) and the controls group (Pune city), where recipients will get a single dose of the BCG vaccination.
According to district health officer Dr. Sachin Desai, the interventional group consisted of people who reported having at least one episode of tuberculosis in the previous five years, people who were in close contact with current tuberculosis patients, people who were exposed to tuberculosis patients, people who were 60 years of age or older, people who self-reported having a history of diabetes, smokers, and people with a body mass index of less than 18.
A population of 3.28 lakh people in Pimpri-Chinchwad was selected for the study, according to Dr. Laxman Gophane, the PCMC’s health officer. 2.78 of the 3.28 lakh individuals decided to have the BCG vaccination. “People ought to come forward and receive the BCG vaccination; we have made vaccination available at eight hospitals,” he declared.
About 4.32 lakh of the 7.65 lakh eligible individuals in Pune Rural accepted to engage in the study, according to Dr. Anjalli Gaikwad, the district program coordinator. “A three-month immunization program will be implemented. A mop-up round will subsequently be conducted to cover the remaining population. People in both groups will then be monitored for the following three years for a variety of reasons, including the vaccine’s efficacy, side effects, how well the treatment works, and how long it will take to heal, she added.
For the next three years, the protective benefits of the BCG vaccination against Mycobacterium tuberculosis infection will be assessed in both vaccinated and unprotected groups.
“The BCG vaccine, which is traditionally given to newborns, is now being explored for its potential to reduce tuberculosis infection among adults and people in the high-risk category,” stated Dr. Vikas Wadgye, the district tuberculosis officer. Such studies have already been conducted in a few states, including Goa and Himachal Pradesh (HP).
Discover more from A Healthfitness
Subscribe to get the latest posts sent to your email.
